Roche, Prothena hus­tle to PhII with their dis­ease-mod­i­fy­ing Parkin­son's drug tar­get­ing al­pha-synu­cle­in

Prothena turned up at the big Alzheimer’s/Parkin­son’s con­fer­ence in Vi­en­na over the week­end to de­tail ear­ly-stage da­ta show­ing how its Roche-part­nered drug PRX002/RG7935 can flush out tox­ic clus­ters of al­pha-synu­cle­in in Parkin­son’s pa­tients. And they used the oc­ca­sion to note the launch of their Phase II study.

In­ves­ti­ga­tors in the Phase Ib tri­al used mul­ti­ple as­cend­ing dos­es of PRX002/RG7935 in Parkin­son’s pa­tients and found that a sin­gle dose could slash free serum al­pha-synu­cle­in lev­els by up to 97%, with the re­sponse main­tained af­ter two month­ly dos­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.